Obsidian Therapeutics (NASDAQ:OBX) Shares Shorted: Short Interest Up 210.7% in September

Obsidian Therapeutics (NASDAQ:OBX) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 253,084 shares, an increase of 210.7% from the August 31st total of 81,457 shares. Based on an average trading volume of 314,739 shares, the short-interest ratio is currently 0.8 days. Approximately 0.4% of the shares of the stock are sold short.

Obsidian Therapeutics Stock Performance

OBX traded down $0.55 during midday trading on Friday, reaching $12.86. 454,476 shares of the company’s stock were exchanged, compared to its average volume of 641,407. Obsidian Therapeutics has a 1-year low of $12.16 and a 1-year high of $49.97.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on OBX shares. Zacks Research upgraded Obsidian Therapeutics to a “hold” rating in a report on Thursday, August 6th. Leerink Partners started coverage on Obsidian Therapeutics in a report on Tuesday. They set an “outperform” rating and a $32.00 price objective for the company. Piper Sandler assumed coverage on Obsidian Therapeutics in a research report on Wednesday, August 5th. They set an “overweight” rating and a $42.00 target price on the stock. Wall Street Zen raised Obsidian Therapeutics to a “sell” rating in a report on Saturday, September 19th. Finally, William Blair assumed coverage on Obsidian Therapeutics in a research report on Wednesday, September 9th. They issued an “outperform” rating for the company. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.00.

Obsidian Therapeutics Company Profile

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.